151 related articles for article (PubMed ID: 35004731)
1. COX-2/sEH Dual Inhibitor PTUPB Alleviates CCl
Zhao Z; Zhang C; Lin J; Zheng L; Li H; Qi X; Huo H; Lou X; Hammock BD; Hwang SH; Bao Y; Luo M
Front Med (Lausanne); 2021; 8():761517. PubMed ID: 35004731
[No Abstract] [Full Text] [Related]
2. Telmisartan relieves liver fibrosis and portal hypertension by improving vascular remodeling and sinusoidal dysfunction.
Zheng L; Zhao Z; Lin J; Li H; Wu G; Qi X; Lou X; Bao Y; Huo H; Luo M
Eur J Pharmacol; 2022 Jan; 915():174713. PubMed ID: 34942161
[TBL] [Abstract][Full Text] [Related]
3. COX-2/sEH Dual Inhibitor Alleviates Hepatocyte Senescence in NAFLD Mice by Restoring Autophagy through Sirt1/PI3K/AKT/mTOR.
Zhang CY; Tan XH; Yang HH; Jin L; Hong JR; Zhou Y; Huang XT
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897843
[TBL] [Abstract][Full Text] [Related]
4. A COX-2/sEH dual inhibitor PTUPB ameliorates cecal ligation and puncture-induced sepsis in mice via anti-inflammation and anti-oxidative stress.
Zhang YF; Sun CC; Duan JX; Yang HH; Zhang CY; Xiong JB; Zhong WJ; Zu C; Guan XX; Jiang HL; Hammock BD; Hwang SH; Zhou Y; Guan CX
Biomed Pharmacother; 2020 Jun; 126():109907. PubMed ID: 32114358
[TBL] [Abstract][Full Text] [Related]
5. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
Schwabl P; Hambruch E; Seeland BA; Hayden H; Wagner M; Garnys L; Strobel B; Schubert TL; Riedl F; Mitteregger D; Burnet M; Starlinger P; Oberhuber G; Deuschle U; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Reiberger T; Kremoser C; Trauner M
J Hepatol; 2017 Apr; 66(4):724-733. PubMed ID: 27993716
[TBL] [Abstract][Full Text] [Related]
6. Dual sEH/COX-2 Inhibition Using PTUPB-A Promising Approach to Antiangiogenesis-Induced Nephrotoxicity.
Jankiewicz WK; Barnett SD; Stavniichuk A; Hwang SH; Hammock BD; Belayet JB; Khan AH; Imig JD
Front Pharmacol; 2021; 12():744776. PubMed ID: 34955823
[TBL] [Abstract][Full Text] [Related]
7. Soluble epoxide hydrolase inhibition with t-TUCB alleviates liver fibrosis and portal pressure in carbon tetrachloride-induced cirrhosis in rats.
Zhang CH; Zheng L; Gui L; Lin JY; Zhu YM; Deng WS; Luo M
Clin Res Hepatol Gastroenterol; 2018 Apr; 42(2):118-125. PubMed ID: 29031875
[TBL] [Abstract][Full Text] [Related]
8. PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in mice.
Sun CC; Zhang CY; Duan JX; Guan XX; Yang HH; Jiang HL; Hammock BD; Hwang SH; Zhou Y; Guan CX; Liu SK; Zhang J
Biochem Biophys Res Commun; 2020 Mar; 523(4):1020-1026. PubMed ID: 31973813
[TBL] [Abstract][Full Text] [Related]
9. COX-2/sEH-Mediated Macrophage Activation Is a Target for Pulmonary Protection in Mouse Models of Chronic Obstructive Pulmonary Disease.
Duan JX; Guan XX; Cheng W; Deng DD; Chen P; Liu C; Zhou Y; Hammock BD; Yang HH
Lab Invest; 2024 Mar; 104(3):100319. PubMed ID: 38158123
[TBL] [Abstract][Full Text] [Related]
10. COX-2/sEH dual inhibitor PTUPB alleviates bleomycin-induced pulmonary fibrosis in mice via inhibiting senescence.
Zhang CY; Duan JX; Yang HH; Sun CC; Zhong WJ; Tao JH; Guan XX; Jiang HL; Hammock BD; Hwang SH; Zhou Y; Guan CX
FEBS J; 2020 Apr; 287(8):1666-1680. PubMed ID: 31646730
[TBL] [Abstract][Full Text] [Related]
11. Effect Of Dual sEH/COX-2 Inhibition on Allergen-Induced Airway Inflammation.
Dileepan M; Rastle-Simpson S; Greenberg Y; Wijesinghe DS; Kumar NG; Yang J; Hwang SH; Hammock BD; Sriramarao P; Rao SP
Front Pharmacol; 2019; 10():1118. PubMed ID: 31611798
[TBL] [Abstract][Full Text] [Related]
12. Curcumin ameliorates intrahepatic angiogenesis and capillarization of the sinusoids in carbon tetrachloride-induced rat liver fibrosis.
Yao Q; Lin Y; Li X; Shen X; Wang J; Tu C
Toxicol Lett; 2013 Sep; 222(1):72-82. PubMed ID: 23845850
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of soluble epoxide hydrolase lowers portal hypertension in cirrhotic rats by ameliorating endothelial dysfunction and liver fibrosis.
Deng W; Zhu Y; Lin J; Zheng L; Zhang C; Luo M
Prostaglandins Other Lipid Mediat; 2017 Jul; 131():67-74. PubMed ID: 28822809
[TBL] [Abstract][Full Text] [Related]
14. Olmesartan Improves Hepatic Sinusoidal Remodeling in Mice with Carbon Tetrachloride-Induced Liver Fibrosis.
Wu Y; Ge X; Wang SN; Zhang CQ
Biomed Res Int; 2022; 2022():4710993. PubMed ID: 36060127
[TBL] [Abstract][Full Text] [Related]
15. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
[TBL] [Abstract][Full Text] [Related]
16. The Beneficial Effects of P2X7 Antagonism in Rats with Bile Duct Ligation-induced Cirrhosis.
Tung HC; Lee FY; Wang SS; Tsai MH; Lee JY; Huo TI; Huang HC; Chuang CL; Lin HC; Lee SD
PLoS One; 2015; 10(5):e0124654. PubMed ID: 25933224
[TBL] [Abstract][Full Text] [Related]
17. Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model.
Theodorakis NG; Wang YN; Wu JM; Maluccio MA; Sitzmann JV; Skill NJ
Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G792-9. PubMed ID: 19628654
[TBL] [Abstract][Full Text] [Related]
18. Soluble epoxide hydrolase deficiency promotes liver regeneration and ameliorates liver injury in mice by regulating angiocrine factors and angiogenesis.
Deng W; Hu T; Xiong W; Jiang X; Cao Y; Li Z; Jiang H; Wang X
Biochim Biophys Acta Gen Subj; 2023 Sep; 1867(9):130394. PubMed ID: 37315719
[TBL] [Abstract][Full Text] [Related]
19. COX-2/sEH dual inhibitor PTUPB suppresses glioblastoma growth by targeting epidermal growth factor receptor and hyaluronan mediated motility receptor.
Li J; Zhou Y; Wang H; Gao Y; Li L; Hwang SH; Ji X; Hammock BD
Oncotarget; 2017 Oct; 8(50):87353-87363. PubMed ID: 29152086
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib Does Not Protect against Fibrosis and Inflammation in a Carbon Tetrachloride-Induced Model of Liver Injury.
Harris TR; Kodani S; Rand AA; Yang J; Imai DM; Hwang SH; Hammock BD
Mol Pharmacol; 2018 Aug; 94(2):834-841. PubMed ID: 29844231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
